Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 13/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18693221 | 0.92 | CFTR (0.73) | CFTRKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL18692892 | 0.91 | CFTR (0.64) | CFTRNPY5R | |
| SCHEMBL18693003 | 0.87 | CFTR (0.61) | CFTRMAPTSMN1; SMN2 | |
| SCHEMBL18693420 | 0.86 | CFTR (0.84) | CFTR | |
| SCHEMBL18693196 | 0.85 | CFTR (0.85) | CFTRKDM4EHPGD | |
| SCHEMBL18692935 | 0.83 | CFTR (0.75) | CFTRKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL18693316 | 0.79 | CFTR (0.86) | CFTR | |
| SCHEMBL18692561 | 0.78 | CFTR (0.60) | CFTRMAPTSMN1; SMN2 | |
| SCHEMBL18693800 | 0.78 | CFTR (0.84) | CFTR | |
| SCHEMBL18693872 | 0.77 | CFTR (1.00) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108513574-B | N-sulfonylated pyrazolo [3, 4-b ] pyridine-6-carboxamides and methods of use | 艾伯维公司 | 2021-01-05 | — | — | CN | claimed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | claimed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | claimed |
| US-9890158-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2018-02-13 | — | — | US | claimed |
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | claimed |
| WO-2017060874-A1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L (LU) | 2017-04-13 | — | — | WO | claimed |
| CN-108513574-B | N-sulfonylated pyrazolo [3, 4-b ] pyridine-6-carboxamides and methods of use | 艾伯维公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | AbbVie S.à.r.l. (LU) | 2019-04-16 | — | — | US | disclosed |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | ABBVIE S.Á.R.L. (LU) | 2018-11-20 | — | — | US | disclosed |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | GALAPAGOS SASU (FR) | 2018-04-19 | — | — | US | disclosed |
| US-9890158-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2018-02-13 | — | — | US | disclosed |
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| WO-2017060874-A1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L (LU) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CFTR 1/4885NPY5R 326/4885MAPT 4879/4885 |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | CFTR, CHRM3, P2RY1 | CFTR 1/4885NPY5R 290/4885MAPT 4876/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CFTR 1/4885NPY5R 326/4885MAPT 4879/4885 |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, CHRM3, P2RY1 | CFTR 1/4885NPY5R 290/4885MAPT 4876/4885 |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | CFTR, CLCN2, SLC26A4 | CFTR 1/4885NPY5R 4785/4885MAPT 4870/4885 |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, P2RY1, P2RX5 | CFTR 1/4885NPY5R 326/4885MAPT 4879/4885 |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CFTR 1/4885NPY5R 326/4885MAPT 4879/4885 |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SLC26A4 | CFTR 1/4885NPY5R 4785/4885MAPT 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.